RESUMO

In our analysis, patients who were treated with intravenous rt-PA had a better outcome than untreated patients, and this effect was not dependent on age. The weight of evidence to date indicates a potential for benefit in older people, and there is no a priori reason to suspect a diminished effect when compared with younger people. The risk of bleeding is similar in both groups. We believe that clinical treatment guidelines should be revised in order to remove the age restriction in the use of intravenous rt-PA acute ischemic stroke.

Assuntos

Acidente Vascular Cerebral/terapia , Terapia Trombolítica/efeitos adversos , Terapia Trombolítica/métodos , Ativador de Plasminogênio Tecidual/uso terapêutico , Fatores Etários , Idoso de 80 Anos ou mais , Gerenciamento Clínico , Humanos , Guias de Prática Clínica como Assunto , Prognóstico , Proteínas Recombinantes/uso terapêutico , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica/normas , Resultado do Tratamento